Holen Sie sich die Stockscreener-App
2.0416
1.37%
-0.0284
Schlusskurs vom Vortag:
$2.07
Offen:
$2.11
24-Stunden-Volumen:
14,603
Relative Volume:
0.06
Marktkapitalisierung:
$13.55M
Einnahmen:
$2.35M
Nettoeinkommen (Verlust:
$-2.56M
KGV:
-4.5561
EPS:
-0.4481
Netto-Cashflow:
-
1W Leistung:
-8.86%
1M Leistung:
+5.78%
6M Leistung:
+20.09%
1J Leistung:
-7.20%
1-Tages-Spanne:
$2.0201
$2.11
1-Wochen-Bereich:
$2.02
$2.30
52-Wochen-Spanne:
$1.50
$2.483
Immuron Limited Adr Stock (IMRN) Company Profile
Firmenname
Immuron Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
2.0201 | 13.88M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.74 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.12 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
329.04 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuron Limited Adr Aktie (IMRN) Neueste Nachrichten
Immuron Limited Announces 2025 Annual General Meeting - TipRanks
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
Immuron Submits IMM-529 IND to FDA - GlobeNewswire Inc.
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - FinancialContent
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
IMC Stock Price and Chart — ASX:IMC - TradingView
Finanzdaten der Immuron Limited Adr-Aktie (IMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
2.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):